Traws Pharma, Inc. Files 8-K
Ticker: TRAW · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Traws Pharma (fka Onconova) filed an 8-K on Jan 23, 2025. Standard corporate update.
AI Summary
On January 23, 2025, Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K report. The filing indicates the company is incorporated in Delaware and provides its business address and phone number. It also lists its Central Index Key as 0001130598 and SEC file number as 001-36020.
Why It Matters
This 8-K filing serves as a public record of Traws Pharma, Inc.'s corporate information and SEC reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that suggests immediate financial or operational risk.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- January 23, 2025 (date) — Date of earliest event reported
- 0001130598 (company) — Central Index Key
- 001-36020 (company) — SEC File Number
- 12 Penns Trail Newtown, PA 18940 (company) — Business Address
- 267-759-3680 (company) — Business Phone
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 23, 2025.
What is the former name of Traws Pharma, Inc.?
Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.
What is the Central Index Key (CIK) for Traws Pharma, Inc.?
The Central Index Key for Traws Pharma, Inc. is 0001130598.
What is the SEC file number for Traws Pharma, Inc.?
The SEC file number for Traws Pharma, Inc. is 001-36020.
Where is Traws Pharma, Inc. incorporated?
Traws Pharma, Inc. is incorporated in Delaware.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2025-01-23 07:00:19
Filing Documents
- tm253126d1_8k.htm (8-K) — 24KB
- tm253126d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-25-005455.txt ( ) — 209KB
- tmb-20250123.xsd (EX-101.SCH) — 3KB
- tmb-20250123_lab.xml (EX-101.LAB) — 33KB
- tmb-20250123_pre.xml (EX-101.PRE) — 22KB
- tm253126d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 23, 2025, Traws Pharma, Inc. (the "Company") issued a press release announcing the completion of the Phase 1 studies for its investigational one-dose influenza therapy, tivoxavir marboxil, for treatment of H5N1 avian influenza. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 23, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 23, 2025 TRAWS PHARMA, INC. By: /s/ Mark Guerin Mark Guerin Chief Financial Officer